Clinical characteristics of monkeypox vaccine injection site reactions: A cohort of seven patients

BackgroundMonkeypox (Mpox) infections are considered a public health emergency, prompting the need for the administration of a preventative vaccine to high-risk individuals.ObjectivesTo describe the clinical course of dermatologic reactions to Mpox vaccine over time.MethodsSeven recipients of the Mpox vaccine, administered via intradermal injection, were observed over time, and the dermatologic reactions to this vaccine were recorded.ResultsAll seven recipients experienced mild to moderate localized reactions to Mpox vaccine to either the primary or booster injections. These reactions were characterized by erythema, induration and pruritus. These reactions eventually healed without any sustained reactions, eschar or scarring. None of the recipients experienced systemic reactions or widespread cutaneous eruptions.ConclusionsIntradermal injections of Mpox vaccine result in mild to moderate injection site reactions, most likely representing a vigorous cell-mediated immune response. In all cases, the injection sites healed without complications. A cohort of seven patients who received intradermal administration of Monkeypox vaccine (a first dose and a booster 28 days later) was followed over time, and the clinical characteristics of the injection site reactions were documented. All seven patients experienced erythema, edema and pruritus at the injection sites for both the first and the booster doses of this vaccine. No systemic reactions were observed. Monkeypox vaccine injection site reactions, while common, resolved without sequelae such as eschar or scarring. image